https://www.selleckchem.com/products/MK-1775.html
Although amphotericin B has been well studied as first line therapy, oral posaconazole has been shown as an efficacious second-line treatment. We outline the second reported case of localized cutaneous mucormycosis arising in the setting of ibrutinib use. Because the combination of immunosuppressed states, ibrutinib and skin trauma may serve as a nidus for mucormycosis, practitioners should be vigilant of thorough skin evaluations in these patients and appropriate anti-fungal treatment. Although amphotericin B has been well studied as f
Like
Comment
Share
